581325-U

Ascentis^® C18 (5 µm) HPLC Columns

L × I.D. 25 cm × 4.6 mm, HPLC Column

• Synonym(s): Ascentis RP18 HPLC Column
• UNSPSC Code: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Properties

• product name: Ascentis^® C18 HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
• material: stainless steel column
• Agency: suitable for USP L1 (Similar to Phenomenex Luna C18)
• product line: Ascentis^®
• feature: endcapped
• manufacturer/tradename: Ascentis^®
• packaging: 1 ea of
• extent of labeling: 25% Carbon loading
• parameter: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• technique(s): HPLC: suitable; LC/MS: suitable
• L × I.D.: 25 cm × 4.6 mm
• surface area: 450 m²/g
• surface coverage: 3.7 μmol/m²
• impurities: <5 ppm metals
• matrix: fully porous particle; silica gel high purity, spherical
• matrix active group: C18 (octadecyl) phase
• particle size: 5 μm
• pore size: 100 Å
• operating pH range: 2-8
• application(s): food and beverages
• separation technique: reversed phase

Description

General description

The Ascentis family of columns is the fourth generation of HPLC column technology from Supelco scientists. Ascentis columns are bonded on high purity, 100 Angstrom silica including 3, 5, and 10 micron particle size. Columns are designed for small molecule applications and are scalable from micro columns (1.0 mm I.D.) to preparative dimensions (50 mm I.D.). The family includes C18, C8, Phenyl, Si and embedded polar group phase, RP-Amide.

Ascentis C18 is an extremely stable and reliable first choice HPLC column that gives symmetric peak shape and excellent retention even for difficult compounds.

Application

• Identification of recombinant human insulin and biosynthetic insulin analogues by multiplexed targeted unlabeled mass spectrometry of proteotypic tryptic peptides.: This study utilized the Ascentis^® C18 HPLC column for the separation of proteotypic tryptic peptides in the identification of insulin analogues, highlighting its application in targeted mass spectrometry for proteomic analysis (Qasem RJ et al., 2019).


• Development and validation of a novel stability-indicating HPLC method for the simultaneous assay of betamethasone-17-valerate, fusidic acid, potassium sorbate, methylparaben and propylparaben in a topical cream preparation.: This research developed and validated an HPLC method using the Ascentis^® C18 HPLC column for the simultaneous assay of multiple compounds, demonstrating its robustness in stability testing of pharmaceutical formulations (Byrne J et al., 2014).


• HPLC-DAD and HPLC-ESI-MS/MS methods for metabolite profiling of propolis extracts.: The study employed the Ascentis^® C18 HPLC column for metabolite profiling of propolis extracts using HPLC-DAD and HPLC-ESI-MS/MS, showcasing its effectiveness in complex natural product analysis (Pellati F et al., 2011).


• Practical comparison of 2.7 microm fused-core silica particles and porous sub-2 microm particles for fast separations in pharmaceutical process development.: This article compared different HPLC column technologies, including the Ascentis^® C18, highlighting its performance in fast separations critical for pharmaceutical process development (Abrahim A et al., 2010).

Features and Benefits

• Excellent retention
• Symmetric peak shape
• High reproducibility
• Complete LC-MS compatibility

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Storage Class Code: 11 - Combustible Solids
• WGK: nwg
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable